Nextrials Debuts iPad Application, Showcases Prism's Interoperability at DIA Annual Meeting
Nextrials, Inc. launched an Apple® iPad™ slate computer application for its clinical trial data management platform, Prism . The application supports mobile access to patient data in clinical trial and health care settings, helping physicians and researchers deliver superior care. It is also usable on an Apple iPhone™, and will be available as a free download later this year through the Apple® iTunes® Store.
Attendees at the 46th Annual Meeting of the Drug Information Association (DIA), being held June 13-17 at the Walter E. Washington Convention Center in Washington, DC, can get a first look at how Prism supports anytime/anywhere data access. In addition, DIA participants will see:
-Prism’s new design tools to foster faster study starts, the result of a recently announced strategic partnership with Formedix
-Nextrials’ participation in a live Healthcare Link demonstration showcasing shared data between clinical trial researchers and healthcare organizations, sponsored by the Clinical Data Interchange Standards Consortium
Nextrials’ Prism melds clinical trial management functionality with EDC in a single package. By receiving a constant flow of data, Prism enables sponsors and sites to fully utilize real-time integration of disparate information and data sources, such as a hospital’s EHR or patient records, to better provide a continuum of care for patients enrolled in clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
